TTY and the international company will jointly develop the overseas market for the Liposome product

2016.7.52016.7.5 最新消息最新消息

TTY and the international company will jointly develop the overseas market for the Liposome product, "Amphotericin B" and "Doxorubicin HCL.” The Upfront Fee for each product will be US$500,000. There will be three separate milestone payments, each at the amount of US$ 1,000,000. The profit sharing will be determined after products are launched in the market.


TOP